Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2008

View Archived Issues

Registry data reveal safety, efficacy of Increlex in children with IGF-1 deficiency

2-Methoxyestradiol a potential marker of and treatment for pre-eclampsia

Papaya mosaic virus vaccine platform triggers responses against influenza challenge

New therapeutic agents for psychiatric disorders reported in recent patent literature

FDA accepts Hemispherx Biopharma's Ampligen NDA for review

Lilly and SGX sign definitive merger agreement

Welichem's phase I WBI-1001 trial meets endpoints in psoriasis

Multikinase inhibitor BIBF-1120 profiled at Boehringer Ingelheim

In vivo efficacy of grape seed polyphenolic extract in a mouse model of Alzheimer's disease

Aloxi launched in the U.S. for prevention of postoperative nausea and vomiting

Loxonin tape 50 mg/100 mg launched in Japan

Polyphor completes phase I POL-6326 trial in hematopoietic stem cell transplantation

FDA approves first organ-specific diagnostic agent in more than a decade

Oligomerix receives grant from ADDF for research on tau oligomers in AD

Starpharma adds treatment of bacterial vaginosis for VivaGel

Paion to initiate phase I clinical study with sedative CNS-7056

Cerimon commences phase II Simulect study in noninfectious uveitis

Arena reports positive results from phase Ib clinical trial of APD-791 in arterial thrombosis

Affymax completes enrollment in phase III PEARL 1 clinical trial of Hematide

Novel antiinflammatory compounds described in recent patents

Samaritan files IND for SP-6310 in HIV patients with abnormal cortisol levels

Merck Serono enrolls first patient in phase II EXPAND trial in gastric cancer

Recent Bristol-Myers Squibb patent discloses new agents for cardiovascular disorders

Fresenius signs sublicense agreement with Luitpold for Venofer in end-stage renal disease

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...